一品红：左卡尼汀口服溶液获得药品注册证书

Core Viewpoint - Yipinhong (300723) announced the approval of its oral solution of L-carnitine by the National Medical Products Administration, which is intended for the treatment of primary systemic carnitine deficiency and secondary carnitine deficiency due to congenital metabolic disorders [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., received the drug registration certificate for L-carnitine oral solution [1] - The approved drug is indicated for both short-term and long-term treatment of specific carnitine deficiencies [1]